Expert Viewpoints in MF

CME

Expert Viewpoints in Myelofibrosis: Advancing Treatment Strategies With Next-Generation Therapeutics

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 07, 2024

Expiration: February 06, 2025

Abdulraheem Yacoub
Abdulraheem Yacoub, MD

Activity

Progress
1 2
Course Completed

References

  1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.
  2. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703-1719.
  3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: myeloproliferative neoplasms. v.1.2024. nccn.org. Accessed January 30, 2024.
  4. Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4:e225-e236.
  5. Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652-659.
  6. Chifotides HT, Bose P, Masarova L, et al. SOHO state of the art updates and next questions: novel therapies in development for myelofibrosis. Clin Lymphoma Myeloma Leuk. 2022;22:210-223.
  7. Greenfield G, McMullin MF, Mills K. Molecular pathogenesis of the myeloproliferative neoplasms. J Hematol Oncol. 2021;14:103.
  8. Harrison CN, Garcia JS, Somervaille TCP, et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy. J Clin Oncol. 2022;40:1671-1680.
  9. Pemmaraju N, Mead AJ, Somervaille TCP, et al. TRANSFORM-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 620.
  10. Rampal RK, Grosicki S, Chraniuk D, et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the manifest-2 randomized, double-blind, phase 3 study. Presented at: 2023 American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023. Abstract 628.
  11. Kremyanskaya M, Mascarenhas J, Palandri F, et al. Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis - update of clinical and translational data from the ongoing Manifest trial. Blood. 2021;138(suppl 1):141.
  12. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395-1398.
  13. Mascarenhas J, Nguyen H, Saunders A, et al. Defining ruxolitinib failure and transition to next-line therapy for patients with myelofibrosis: a modified Delphi panel consensus study. Future Oncol. 2023;19:763-773.
  14. Sureau L, Orvain C, Ianotto JC, et al. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. Blood Cancer J. 2021;11:135.
  15. Pardanani A, Tefferi A, Masszi T, et al. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. Br J Haematol. 2021;195:244-248.
  16. Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study [published correction appears in Lancet. 2023;401:1426] [published correction appears in Lancet. 2023;402:2196]. Lancet. 2023;401:269-280.
  17. Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol. 2017;35:3844-3850.
  18. Yacoub A, Patnaik MM, Ali H, et al. A phase 1/2 study of single agent tagraxofusp, a first-in-class CD123-targeted therapy, in patients with myelofibrosis that is relapsed/refractory following JAK inhibitor therapy. Blood. 2021;138(suppl 1):140.